945103-76-4

Usage

Chemical Structure

Heterocyclic compound containing an imidazolidine ring and a phenyl group with a tert-butyl substitution

Uses

Chemical intermediate in pharmaceutical and organic compound synthesis

Biological/Pharmacological Properties

Studied for potential medicinal uses, such as in treatment of inflammatory diseases and as an antibacterial agent

Research Focus

Pharmaceutical industry interest due to unique structure and reactivity of the compound

Upstream product

• 3972-65-4 1-bromo-4-tert-butylbenzene 
• 77-71-4 5,5-dimethyl-imidazolidine-2,4-dione 
• 253185-03-4 tert-butylbenzene 
• 84563-54-2 bis(4-tert-butylphenyl)iodonium trifluoromethanesulfonate 
• 1943-67-5 4-(t-butyl)phenyl isocyanate 
• 15028-41-8 methyl 2-aminoisobutyrate hydrochloride 

Downstream Products

• 945104-02-9 3-(4-tert-butyl-phenyl)-1-(2-chloro-pyridin-4-ylmethyl)-5,5-dimethyl-imidazolidine-2,4-dione 

Relevant academic research and scientific papers

N1- and N3-Arylations of Hydantoins Employing Diaryliodonium Salts via Copper(I) Catalysis at Room Temperature

Copper(I)-catalyzed N-arylation (both N1- and N3-) of hydantoins with diaryliodonium salts as aryl partners at room temperature is reported. The transformation allows diverse scopes on both hydantoins and diaryliodonium salts deliver

Copper-Mediated N-Arylations of Hydantoins

A set of two broadly applicable procedures for the N-arylation of hydantoins is reported. The first one relies on the use of stoichiometric copper(I) oxide under ligand- A nd base-free conditions and enables a clean regioselective arylation at the N3 nitrogen atom, while the second one is based on the use of catalytic copper(I) iodide and trans-N,N′-dimethylcyclohexane-1,2-diamine and promotes arylation at the N1 nitrogen atom. Importantly, the combination of these two procedures affords a straightforward entry to diarylated hydantoins.

Novel Cyclic Urea Derivatives, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors

Compounds of formula (I): wherein Ra, Rb, R, X1 and X2 are as defined in the disclosure, pharmaceutical compositions comprising said compounds, processes for making and methods of using the same are provided.